Definition of low disease activity state based on the SLE-DAS: derivation and validation in a multicentre real-life cohort

被引:17
作者
Assuncao, Helena [1 ]
Jesus, Diogo [2 ,3 ]
Larosa, Maddalena [4 ]
Henriques, Carla [5 ,6 ]
Matos, Ana [5 ,7 ]
Le Guern, Veronique [8 ,9 ]
Rubino, Francisco [10 ]
da Silva, Jose A. P. [1 ,11 ]
Rua-Figueroa, Inigo [10 ]
Costedoat-Chalumeau, Nathalie [8 ,9 ]
Doria, Andrea [4 ]
Ines, Luis S. [1 ,3 ]
机构
[1] Ctr Hosp & Univ Coimbra, Rheumatol Dept, Coimbra, Portugal
[2] Ctr Hosp Leiria, Rheumatol Dept, Leiria, Portugal
[3] Univ Beira Interior, Fac Hlth Sci, Covilha, Portugal
[4] Univ Padua, Div Rheumatol, Padua, Italy
[5] Polytech Inst Viseu, Sch Technol & Management, Viseu, Portugal
[6] Univ Coimbra, Ctr Math, Coimbra, Portugal
[7] Polytech Viseu, CISeD Res Ctr Digital Serv, Viseu, Portugal
[8] Cochin Hosp, AP HP, Internal Med Dept, Paris, France
[9] Univ Paris, Paris, France
[10] Doctor Negrin Univ Hosp, Rheumatol Dept, Las Palmas Gran Canaria, Spain
[11] Univ Coimbra, Fac Med, Coimbra, Portugal
关键词
systemic lupus erythematosus; treat-to-target; SLE-DAS; LLDAS; SYSTEMIC-LUPUS-ERYTHEMATOSUS; TREAT-TO-TARGET; REMISSION; DAMAGE; RECOMMENDATIONS; ATTAINMENT; LLDAS;
D O I
10.1093/rheumatology/keab895
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives. To derive and validate a definition of low disease activity (LDA) for SLE based on the SLE Disease Activity Score (SLE-DAS), in a real-life multicentre cohort of SLE patients. Methods. Derivation was conducted using data from a monocentric cohort of SLE (Portugal), and validation was performed in a multicentre cohort (Italy, France and Spain). The Lupus Low Disease Activity State (LLDAS) was used as comparator. We applied receiver operating characteristics curve analysis against the LLDAS to determine the cut-off of SLE-DAS for LDA using bootstrap methodology. In a second step, we tested a definition of SLE-DAS LDA that included: (i) the statistically derived SLE-DAS upper threshold for LDA and (ii) prednisone dose <= 7.5 mg/day. In the multicentre validation cohort, we assessed the classification performance of this SLE-DAS LDA definition. Results. We included 774 patients, 300 in the derivation and 474 in the validation cohort. In the derivation cohort, the optimal cut-off to identify patients in LLDAS was SLE-DAS <= 2.48, presenting an area under the curve of 0.965 (95% CI 0.935, 0.994). When applied to the multicentre validation cohort, the SLE-DAS LDA definition showed a sensitivity of 97.1% and a specificity of 97.7% for LLDAS and an almost perfect agreement (Cohen's Kappa =0.933; P < 0.001). McNemar's test found no significant differences between the two definitions (P = 0 .092). Conclusion. The SLE-DAS LDA is a validated, accurate and easy-to-use definition for classifying SLE patients in LDA state.
引用
收藏
页码:3309 / 3316
页数:8
相关论文
共 42 条
  • [1] Validity of systemic lupus erythematosus disease activity score (SLE-DAS) for definition of lupus low disease activity state (LLDAS)
    Abdelhady, Enas, I
    Rabie, Mona
    Hassan, Rofaida A.
    [J]. CLINICAL RHEUMATOLOGY, 2021, 40 (11) : 4553 - 4558
  • [2] Independent association of glucocorticoids with damage accrual in SLE
    Apostolopoulos, Diane
    Kandane-Rathnayake, Rangi
    Raghunath, Sudha
    Hoi, Alberta
    Nikpour, Mandana
    Morand, Eric F.
    [J]. LUPUS SCIENCE & MEDICINE, 2016, 3 (01):
  • [3] Long-term outcomes in systemic lupus erythematosus: trends over time and major contributors
    Arnaud, Laurent
    Tektonidou, Maria G.
    [J]. RHEUMATOLOGY, 2020, 59 : 29 - 38
  • [4] Bekkar M., 2013, J INF ENG APPL, V3, P27, DOI DOI 10.5121/IJDKP.2013.3402
  • [5] Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort
    Bruce, Ian N.
    O'Keeffe, Aidan G.
    Farewell, Vern
    Hanly, John G.
    Manzi, Susan
    Su, Li
    Gladman, Dafna D.
    Bae, Sang-Cheol
    Sanchez-Guerrero, Jorge
    Romero-Diaz, Juanita
    Gordon, Caroline
    Wallace, Daniel J.
    Clarke, Ann E.
    Bernatsky, Sasha
    Ginzler, Ellen M.
    Isenberg, David A.
    Rahman, Anisur
    Merrill, Joan T.
    Alarcon, Graciela S.
    Fessler, Barri J.
    Fortin, Paul R.
    Petri, Michelle
    Steinsson, Kristjan
    Dooley, Mary Anne
    Khamashta, Munther A.
    Ramsey-Goldman, Rosalind
    Zoma, Asad A.
    Sturfelt, Gunnar K.
    Nived, Ola
    Aranow, Cynthia
    Mackay, Meggan
    Ramos-Casals, Manuel
    van Vollenhoven, Ronald F.
    Kalunian, Kenneth C.
    Ruiz-Irastorza, Guillermo
    Lim, Sam
    Kamen, Diane L.
    Peschken, Christine A.
    Inanc, Murat
    Urowitz, Murray B.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 (09) : 1706 - 1713
  • [6] Use of Physician Global Assessment in systemic lupus erythematosus: a systematic review of its psychometric properties
    Chessa, Elisabetta
    Piga, Matteo
    Floris, Alberto
    Devilliers, Herve
    Cauli, Alberto
    Arnaud, Laurent
    [J]. RHEUMATOLOGY, 2020, 59 (12) : 3622 - 3632
  • [7] Optimizing outcome in SLE: treating-to-target and definition of treatment goals
    Doria, Andrea
    Gatto, Mariele
    Zen, Margherita
    Iaccarino, Luca
    Punzi, Leonardo
    [J]. AUTOIMMUNITY REVIEWS, 2014, 13 (07) : 770 - 777
  • [8] 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus
    Fanouriakis, Antonis
    Kostopoulou, Myrto
    Alunno, Alessia
    Aringer, Martin
    Bajema, Ingeborg
    Boletis, John N.
    Cervera, Ricard
    Doria, Andrea
    Gordon, Caroline
    Govoni, Marcello
    Houssiau, Frederic
    Jayne, David
    Kouloumas, Marios
    Kuhn, Annegret
    Larsen, Janni L.
    Lerstrom, Kirsten
    Moroni, Gabriella
    Mosca, Marta
    Schneider, Matthias
    Smolen, Josef S.
    Svenungsson, Elisabet
    Tesar, Vladimir
    Tincani, Angela
    Troldborg, Anne
    van Vollenhoven, Ronald
    Wenzel, Joerg
    Bertsias, George
    Boumpas, Dimitrios T.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 (06) : 736 - 745
  • [9] Low disease activity-irrespective of serologic status at baseline-associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: A real-life observational study
    Fanouriakis, Antonis
    Adamichou, Christina
    Koutsoviti, Sofia
    Panopoulos, Stylianos
    Staveri, Chrysanthi
    Klagou, Anastasia
    Tsalapaki, Christina
    Pantazi, Lamprini
    Konsta, Styliani
    Mavragani, Clio P.
    Dimopoulou, Despoina
    Ntali, Styliani
    Katsikas, Georgios
    Boki, Kyriaki A.
    Vassilopoulos, Dimitrios
    Konstantopoulou, Pinelopi
    Liossis, Stamatis-Nick
    Elezoglou, Antonia
    Tektonidou, Maria
    Sidiropoulos, Prodromos
    Erden, Abdulsamet
    Sfikakis, Petros R.
    Bertsias, George
    Boumpas, Dimitrios T.
    [J]. SEMINARS IN ARTHRITIS AND RHEUMATISM, 2018, 48 (03) : 467 - 474
  • [10] Remission and Low Disease Activity Status (LDAS) protect lupus patients from damage occurrence: data from a multiethnic, multinational Latin American Lupus Cohort (GLADEL)
    Francisco Ugarte-Gil, Manuel
    Wojdyla, Daniel
    Pons-Estel, Guillermo J.
    Catoggio, Luis J.
    Drenkard, Cristina
    Sarano, Judith
    Berbotto, Guillermo A.
    Borba, Eduardo F.
    Inoue Sato, Emilia
    Tavares Brenol, Joao C.
    Uribe, Oscar
    Ramirez Gomez, Luis A.
    Guibert-Toledano, Marlene
    Massardo, Loreto
    Cardiel, Mario H.
    Silveira, Luis H.
    Chacon-Diaz, Rosa
    Alarcon, Graciela S.
    Pons-Estel, Bernardo A.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (12) : 2071 - 2074